NEW YORK, March 21, 2018 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Kraton Corporation (NYSE:KRA) from October 25, 2017 through February 21, 2018, both dates inclusive (“Class Period”). The lawsuit seeks to recover damages for Kraton investors under the federal securities laws.
To join the Kraton class action, go to http://www.rosenlegal.com/cases-1299.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Kraton was transitioning customers to Brazilian-produced Cariflex even though certain customers had already rejected that product; (2) Kraton’s Brazilian-produced Cariflex was available to customers when in fact certain customers had already rejected that product; (3) Kraton lacked effective internal controls over financial reporting; and (4) as a result, defendants’ statements about Kraton’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 27, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1299.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 



